Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴
46.1K posts

Richard Garcia 🇩🇴
@richddr
🇩🇴 ➡️SF➡️MA➡️FL. Software Engineer @IncludedHealth. funny from time to time. potatoe. personal account.
Tampa, FL Katılım Haziran 2009
1.6K Takip Edilen569 Takipçiler
Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴 retweetledi

Carlos ganador de #PlanetaAlofoke merecido 100% cargo la casa 1 y no la ganó porque entró tarde, no ganó la casa 2 porque llegó un fenómeno como La Fruta y ahora gana el primer lugar. La constancia se premia, Carlos es sin lugar a dudas el mejor creador de contenido dominicano
Español
Richard Garcia 🇩🇴 retweetledi

1/5
I'm a cardiologist. I have spent twenty years watching cholesterol destroy arteries, trigger heart attacks, and kill people I care about.
Today, Eli Lilly presented data that may begin to end that era.
VERVE-102. A single infusion. One dose. It uses base editing to permanently turn off the PCSK9 gene in your liver.
Presented today at the European Atherosclerosis Society Congress:
88% reduction in PCSK9.
62% reduction in LDL cholesterol.
Sustained up to 18 months.
No treatment-related serious adverse events.
One infusion. Not daily pills you forget to take. Not monthly injections. One dose — and your cholesterol may stay low for the rest of your life.
English
Richard Garcia 🇩🇴 retweetledi

Richard Garcia 🇩🇴 retweetledi

One injection, 62% lower LDL - permanently. Gene editing for cholesterol is here.
.@cremieuxrecueil is correct. Besides GLP-1 antagonist like Ozempic or, more recently, Retatrutide, this is probably the next breakthrough that is almost impossible to put into words.
Verve Therapeutics (Eli Lilly) just published Phase 1 results for VERVE-102 in the NEJM.
It's a single-infusion base-editing therapy that inactivates PCSK9 in the liver. At the highest dose, PCSK9 dropped 88% and LDL cholesterol fell 62%. Reductions held for at least a year.
35 patients with familial hypercholesterolemia or premature coronary artery disease. No dose-limiting toxicities. Main side effects: mild infusion reactions and transient liver enzyme elevations.
Still Phase 1, still small, no cardiovascular outcome data yet. But the proof of concept for permanent, one-shot LDL reduction via gene editing is real.
This is an absolute game changer and im not exaggerting.
Elevated LDL cholesterol is responsible for an estimated 4.4 million deaths every year worldwide and remains the single biggest modifiable driver of cardiovascular disease, the leading cause of death globally.

Crémieux@cremieuxrecueil
Eli Lilly has done it. They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!
English
Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴 retweetledi
Richard Garcia 🇩🇴 retweetledi



















